Get the Stockscreener App
4.33
1.37%
-0.06
Recursion Pharmaceuticals Inc stock is traded at $4.33, with a volume of 14.66M.
It is down -1.37% in the last 24 hours and down -6.88% over the past month.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
See More
Previous Close:
$4.39
Open:
$4.52
24h Volume:
14.66M
Relative Volume:
0.60
Market Cap:
$2.32B
Revenue:
$64.60M
Net Income/Loss:
$-377.75M
P/E Ratio:
-2.7935
EPS:
-1.55
Net Cash Flow:
$-335.64M
1W Performance:
-24.04%
1M Performance:
-6.88%
6M Performance:
-39.01%
1Y Performance:
-49.88%
1-Day Range:
$4.31
$4.63
1-Week Range:
$4.11
$5.80
52-Week Range:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Name
Recursion Pharmaceuticals Inc
Sector
Industry
Phone
(385) 269-0203
Address
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
4.33 | 2.32B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-23 | Initiated | Morgan Stanley | Equal-Weight |
| Mar-16-23 | Initiated | Needham | Buy |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Apr-18-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-21 | Initiated | Berenberg | Buy |
| May-11-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Goldman | Neutral |
| May-11-21 | Initiated | JP Morgan | Neutral |
| May-11-21 | Initiated | KeyBanc Capital Markets | Overweight |
| May-11-21 | Initiated | SVB Leerink | Outperform |
View All
Recursion Pharmaceuticals Inc Stock (RXRX) Latest News
Recursion Pharmaceuticals files prospectus supplement - Investing.com
Recursion Pharmaceuticals Registers Shares for Resale - TipRanks
Why Recursion Pharmaceuticals Stock Plummeted 24% This Week - The Motley Fool
Why Recursion Pharmaceuticals Stock Plummeted 24% This Week - Nasdaq
(RXRX) Long Term Investment Analysis - news.stocktradersdaily.com
Retail Traders Bearish On Recursion Pharma Ahead of Q1 Results Despite Positive Tupelo Trial Data - MSN
RXRX Stock Down 17% as Q1 Earnings & Revenues Miss Estimates - MSN
Earnings Release: Here's Why Analysts Cut Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Price Target To US$7.43 - Yahoo Finance
Why Recursion Pharmaceuticals Stock Is Plummeting Today - The Globe and Mail
Recursion axes drug programmes to streamline pipeline - Yahoo Finance
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q1 2025 Earnings Call Transcript - Insider Monkey
Recursion to Participate in Upcoming Investor Conferences - The Manila Times
BofA Adjusts Price Target for RXRX Following Pipeline Changes | RXRX Stock News - GuruFocus
Recursion Pharmaceuticals Inc (RXRX) Q1 2025 Earnings Call Highlights: Strategic Partnerships ... By GuruFocus - Investing.com Canada
Recursion Pharmaceuticals (RXRX) Advances Drug Programs with Str - GuruFocus
Recursion Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Recursion Pharmaceuticals: Q1 Earnings Snapshot - MySA
Recursion Pharmaceuticals’ Earnings Call: Balancing Success and Challenges - TipRanks
Recursion Pharmaceuticals Q1 2025 Earnings: EPS Beats Estimates at -$0.50, Revenue Misses at $15 Million - GuruFocus
Recursion Pharmaceuticals (RXRX) Reports Q1 Earnings: EPS Surpas - GuruFocus
Recursion (RXRX) Reports Q1 Revenue Shortfall, Focuses on Stream - GuruFocus
Why Recursion Pharmaceuticals Stock Was Getting Mashed on Monday - Mitrade
Earnings call transcript: Recursion Pharmaceuticals Q1 2025 results miss estimates By Investing.com - Investing.com South Africa
Earnings call transcript: Recursion Pharmaceuticals Q1 2025 results miss estimates - Investing.com Nigeria
Recursion Pharmaceuticals (RXRX) Advances Drug Programs with Strategic Focus - GuruFocus
Recursion Pharmaceuticals (NasdaqGS:RXRX) Reports Q1 Sales Increase and REC-4881 Trial Results - Yahoo Finance
Recursion Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
AI specialist Recursion trims pipeline in latest shakeup - BioPharma Dive
Why Recursion Pharmaceuticals Stock Was Getting Mashed On Monday - Barchart.com
Recursion Deprioritizes 3 Clinical Programs Following Data-Driven Review, Stock Down - Nasdaq
Document - SEC.gov
Recursion Pharmaceuticals earnings missed by $0.01, revenue fell short of estimates - Investing.com Canada
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Recursion Pharmaceuticals Q1 Loss Widens, Revenue Increases - marketscreener.com
Recursion Pharmaceuticals Reports Q1 Results and Strategy Update - TipRanks
RECURSION PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Recursion Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Recursion Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Recursion Halts Four Pipeline Programs, Sharpening Cancer, Rare Disease Focus - Genetic Engineering and Biotechnology News
Recursion Pharmaceuticals Reports Promising Early Results for Familial Adenomatous Polyposis Drug Trial - marketscreener.com
Recursion Pharmaceuticals: Looking For Entry Around Q1 Earnings (NASDAQ:RXRX) - Seeking Alpha
Recursion (RXRX) Reports Promising Results for FAP Treatment - GuruFocus
Preliminary Phase 1b/2 Data for REC-4881 in Familial - GlobeNewswire
Recursion's REC-4881 Shows Promising Results in TUPELO Trial | R - GuruFocus
Recursion's REC-4881 Shows Promising Results in TUPELO Trial | RXRX Stock News - GuruFocus
Recursion Pharmaceuticals (RXRX) Set to Release Q1 Earnings - GuruFocus
Did Jim Cramer Nail All These 9 Stock Predictions? - Insider Monkey
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing - MSN
Was Jim Cramer Right About Recursion Pharmaceuticals, Inc. (RXRX)? - Insider Monkey
Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th - Bluefield Daily Telegraph
Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):